Table 4.

Association of serum IGF-I and IGFBP-3 concentration with risk of low-grade and high-grade prostate cancer in EPIC

Low grade*
High grade
Pheterogeneity
No. cases/controlsOR (95% CI)No. cases/controlsOR (95% CI)
IGF-I
    Low79/1011.0047/431.00
    Medium113/971.58 (1.03-2.42)56/530.96 (0.56-1.65)
    High117/1111.45 (0.94-2.22)43/500.77 (0.42-1.41)
    Ptrend0.060.340.06
Residuals of IGF-I adjusted for IGFBP-3
    Low79/1011.0047/431.00
    Medium113/971.27 (0.84-1.93)56/531.11 (0.59-2.08)
    High117/1111.27 (0.82-1.97)43/501.31 (0.71-2.41)
    Ptrend0.140.690.25
IGFBP-3
    Low86/1011.0054/471.00
    Medium117/1111.27 (0.85-1.89)40/460.79 (0.46-1.34)
    High106/971.33 (0.87-2.03)52/530.86 (0.49-1.53)
    Ptrend0.240.290.12
Residuals of IGBP-3 adjusted for IGF-I
    Low106/1111.0050/521.00
    Medium111/1031.14 (0.76-1.69)47/471.05 (0.58-1.92)
    High92/951.02 (0.66-1.57)49/471.11 (0.59-2.07)
    Ptrend0.950.550.65
  • * Based on 309 case-control pairs where the case was diagnosed with low-grade disease.

  • Based on 146 case-control pairs where the case was diagnosed with high-grade disease.

  • Ptrend based on the continuous (log transformed) variable.